Market trends · on the rundown Friday, October 23, 2026
Personalized mRNA vaccine reports show lower melanoma return risk
Covered by 41 outlets over 183 hours. First reported by K8 News | Jonesboro, Arkansas at 00:45 UTC on October 23, 2026.
- outlets41
- distinct reports41
- first to latest report183 h
- names in it4
What happened?
- The RNA Foundry lists a personalized cancer vaccine at $300,000 and says its Hyderabad, India facility can run 24/7 to produce individualized RNA vaccines.
- The RNA Foundry is a project of PopVax with Stochastic Sciences and states it operates a GMP-compliant RNA manufacturing facility in Hyderabad.
- The company states its lipid nanoparticle formulation using ionizable lipid PVXL-150 stays stable for 9+ months at 2-8 degrees Celsius.
Merck's chief executive told CNBC the prescribing community would find the results quite meaningful. Separately, the RNA Foundry listed a contract service to manufacture personalized cancer vaccines at $300,000 from its GMP facility in Hyderabad, India.
A machine summary written from the reports listed below; read them for the full account. How summaries are made and what is checked.
Who reported it, and when?
A report's title is shown once our automated legal check has read it and passed it; 33 reports are named by outlet, and the links lead to each report.
Who was named?
- RNA Foundry
- Stochastic Sciences
- PopVax
- PVXL-150
Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).